Enteral nutrition for esophageal cancer patients with concurrent chemoradiotherapy

Jia-hua LV,Tao LI,Guang-ying ZHU,Jie LI,Shu-chai ZHU,Jian-hua WANG,Li-gang XING,Dao-ke YANG,Cong-hua XIE,Liang-fang SHEN,Jin-yi LANG,Han-ping SHI
DOI: https://doi.org/10.16689/j.cnki.cn11-9349/r.2016.04.010
2016-01-01
Abstract:Objective To evaluate the change of body weight, nutritional status, efficacy and safety of concurrent chemoradiotherapy combined with or without enteral nutrition for esophageal carcinoma.Methods Patients with esophageal carcinoma in accordance with inclusion criteria were randomly assigned to experimental group and the control group. Both groups of patients received at least 2 cycles of chemotherapy with cisplatin and docetaxel every 3 weeks concurrent with radiotherapy. Patients in concurrent chemoradiotherapy experimental group received enteral nutrition containing 10~25kcal/(kg·d) according to swallowing obstruction,dietary structure,amount of food intake, in addition to regular diets. The primary end point was weight loss and the secondary end points were nutrition related index, toxicity and clinical effect.Results Between Sep. 2014 and Feb. 2016, 88 patients were enrolled and divided into the experimental group (n=58) and the control group (n=30). The baseline clinical characteristics of the 2 groups were similar. The average loss of body weight of experimental group was lower than the control group [(2.26±0.64)kg vs. (5.45±2.94)kg,P>0.05]. The average loss of body mass index in experimental group was lower than the control group (0.88±0.25 vs. 2.08±1.12,P>0.05). The nutrition related indicators such as hemoglobin, serum albumin, total lymphocyte count of experimental group were better than the control group, there were no statistical differences except for serum albumin (P>0.05). The objective remission rate of the experimental group was 90.4%, while the control group was 86.7% (P>0.05). In adverse reactions, experimental group with equal or greater than grade 3 hematologic adverse reactions were signiifcantly lower than the control group (31.1% vs.&nbsp;45.7%,P<0.05). The acute radiation esophagitis and acute radiation pneumonia were no statistical differences (P>0.05).Conclusions Enteral nutrition can reduce the weight loss of esophageal cancer patients during chemoradiotherapy, improve nutritional status and treatment tolerance, reduce toxicity, but we need to enroll more patients to conifrm these results.
What problem does this paper attempt to address?